Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT
Objectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, [<sup>68</sup>Ga]Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/24/6039 |
| _version_ | 1797461061723488256 |
|---|---|
| author | Mehmet Asim Bilen Akinyemi Akintayo Yuan Liu Olayinka Abiodun-Ojo Omer Kucuk Bradley C. Carthon David M. Schuster Ephraim E. Parent |
| author_facet | Mehmet Asim Bilen Akinyemi Akintayo Yuan Liu Olayinka Abiodun-Ojo Omer Kucuk Bradley C. Carthon David M. Schuster Ephraim E. Parent |
| author_sort | Mehmet Asim Bilen |
| collection | DOAJ |
| description | Objectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, [<sup>68</sup>Ga]Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NePC). This study explores the utility of [<sup>68</sup>Ga]Ga-DOTATATE PET-CT to identify metastatic deposits in men with mCRPC and NePC and prognosticate disease progression. Methods: [<sup>68</sup>Ga]Ga-DOTATATE PET-CT was performed in 17 patients with mCRPC and of those, 2/17 had NePC. A semiquantitative analysis with standardized uptake values (SUV) (e.g., SUVmax, SUVmean) was performed for each metastatic lesion and reference background tissues. [<sup>68</sup>Ga]Ga-DOTATATE uptake in metastatic deposits was further classified as: mild (less than liver), moderate (up to liver average), or marked (greater than liver). Serial prostate-specific antigen measurements and patient survival were followed up to 3 years after PET imaging to assess response to standard of care treatment. Results: All patients had at least one metastatic lesion with identifiable [<sup>68</sup>Ga]Ga-DOTATATE uptake. Marked [<sup>68</sup>Ga]Ga-DOTATATE uptake was found in 7/17 patients, including both NePC patients, and all were non-responders to systemic therapy and died within the follow up period, with a mean time to death of 8.1 months. Three patients had mild [<sup>68</sup>Ga]Ga-DOTATATE uptake, and all were responders to systemic therapy and were alive 36 months after [<sup>68</sup>Ga]Ga-DOTATATE imaging. Conclusions: [<sup>68</sup>Ga]Ga-DOTATATE is able to identify mCRPC and NePC metastatic deposits, and lesions with [<sup>68</sup>Ga]Ga-DOTATATE uptake > liver may portend poor outcomes in patients with mCRPC. |
| first_indexed | 2024-03-09T17:14:03Z |
| format | Article |
| id | doaj.art-1e2d55b3ec01465f91e5dd352a79b6b6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T17:14:03Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1e2d55b3ec01465f91e5dd352a79b6b62023-11-24T13:45:08ZengMDPI AGCancers2072-66942022-12-011424603910.3390/cancers14246039Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CTMehmet Asim Bilen0Akinyemi Akintayo1Yuan Liu2Olayinka Abiodun-Ojo3Omer Kucuk4Bradley C. Carthon5David M. Schuster6Ephraim E. Parent7Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USADepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USAWinship Cancer Institute, Emory University, Atlanta, GA 30322, USADepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USADepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USADepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USADepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USAObjectives: Prostate cancer is well known to express high levels of somatostatin receptors and preliminary data suggests that PET imaging with the somatostatin analog, [<sup>68</sup>Ga]Ga-DOTATATE, may allow for whole body staging of patients with metastatic castration resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NePC). This study explores the utility of [<sup>68</sup>Ga]Ga-DOTATATE PET-CT to identify metastatic deposits in men with mCRPC and NePC and prognosticate disease progression. Methods: [<sup>68</sup>Ga]Ga-DOTATATE PET-CT was performed in 17 patients with mCRPC and of those, 2/17 had NePC. A semiquantitative analysis with standardized uptake values (SUV) (e.g., SUVmax, SUVmean) was performed for each metastatic lesion and reference background tissues. [<sup>68</sup>Ga]Ga-DOTATATE uptake in metastatic deposits was further classified as: mild (less than liver), moderate (up to liver average), or marked (greater than liver). Serial prostate-specific antigen measurements and patient survival were followed up to 3 years after PET imaging to assess response to standard of care treatment. Results: All patients had at least one metastatic lesion with identifiable [<sup>68</sup>Ga]Ga-DOTATATE uptake. Marked [<sup>68</sup>Ga]Ga-DOTATATE uptake was found in 7/17 patients, including both NePC patients, and all were non-responders to systemic therapy and died within the follow up period, with a mean time to death of 8.1 months. Three patients had mild [<sup>68</sup>Ga]Ga-DOTATATE uptake, and all were responders to systemic therapy and were alive 36 months after [<sup>68</sup>Ga]Ga-DOTATATE imaging. Conclusions: [<sup>68</sup>Ga]Ga-DOTATATE is able to identify mCRPC and NePC metastatic deposits, and lesions with [<sup>68</sup>Ga]Ga-DOTATATE uptake > liver may portend poor outcomes in patients with mCRPC.https://www.mdpi.com/2072-6694/14/24/6039DOTATATEPETprostate cancerneuroendocrine prostate cancer |
| spellingShingle | Mehmet Asim Bilen Akinyemi Akintayo Yuan Liu Olayinka Abiodun-Ojo Omer Kucuk Bradley C. Carthon David M. Schuster Ephraim E. Parent Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT Cancers DOTATATE PET prostate cancer neuroendocrine prostate cancer |
| title | Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT |
| title_full | Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT |
| title_fullStr | Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT |
| title_full_unstemmed | Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT |
| title_short | Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [<sup>68</sup>Ga]Ga DOTATATE PET-CT |
| title_sort | prognostic evaluation of metastatic castration resistant prostate cancer and neuroendocrine prostate cancer with sup 68 sup ga ga dotatate pet ct |
| topic | DOTATATE PET prostate cancer neuroendocrine prostate cancer |
| url | https://www.mdpi.com/2072-6694/14/24/6039 |
| work_keys_str_mv | AT mehmetasimbilen prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT akinyemiakintayo prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT yuanliu prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT olayinkaabiodunojo prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT omerkucuk prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT bradleyccarthon prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT davidmschuster prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct AT ephraimeparent prognosticevaluationofmetastaticcastrationresistantprostatecancerandneuroendocrineprostatecancerwithsup68supgagadotatatepetct |